Stocks Health care LRMR
NASDAQ · Health careLarimar Therapeutics, Inc. (LRMR)
It posted a net loss of $172.6M. In fiscal 2025 capital spending exceeded operating cash flow by $113.3M. At June 30, 2026 it held $92.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
Key facts about Larimar Therapeutics, Inc.
- Net worth
- Larimar Therapeutics, Inc. has a market value (market cap) of $262.8M at the latest share price, and shareholders' equity of $127.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2019 revenue was $0, with a net loss of $23.1M.
- Cash flow
- In fiscal 2025 operations used $113.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 4, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Larimar Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Larimar Therapeutics, Inc. does
Larimar Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LRMR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$165.7M | n/a | -$113.3M |
| 2024 | n/a | -$80.6M | -$1.32 | -$71.3M |
| 2023 | n/a | -$36.9M | -$0.84 | -$33.6M |
| 2022 | n/a | -$35.4M | -$1.37 | -$27.7M |
| 2021 | n/a | -$50.6M | -$2.95 | -$42.4M |
| 2020 | n/a | -$42.5M | -$3.57 | -$42.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Larimar Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- September 29, 2026Executive or director change8-KLarimar Therapeutics appointed John B. Harlow, Jr. as President and Chief Operating Officer effective September 29, 2026.
- August 4, 2026
- August 4, 2026
- June 29, 2026Other event 8-K
- May 19, 2026
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026
- May 14, 2026
- April 30, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Larimar Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 29, 2026 | Harlow John B. Jr.President and COO | Received as pay | 50,000 | - |
| July 6, 2026 | Hamilton Thomas EdwardDirector | Bought | 50,000 | $166.9K |
| February 27, 2026 | Sherman Jeffrey WDirector | Bought | 5,000 | $25K |
| February 27, 2026 | Thomas Frank EDirector | Bought | 5,000 | $25K |
| February 27, 2026 | Hamilton Thomas EdwardDirector | Bought | 100,000 | $500K |
| February 27, 2026 | Flynn James EDirector, 10% owner | Boughtindirect | 1,084,010 | $5.4M |
| February 27, 2026 | Flynn James EDirector, 10% owner | Boughtindirect | 1,084,012 | $5.4M |
| February 27, 2026 | Flynn James EDirector, 10% owner | Boughtindirect | 831,978 | $4.2M |
Who owns LRMR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Deerfield Management Company, L.P.13D, may seek influence with 9 related filers | 34.41% | March 2, 2026 |
| Blue Owl Capital Holdings LP13G, passive | 9.99% | May 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 163 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Deerfield Management Company, L.P. | 35,606,974 | 0 |
| Blue Owl Capital Holdings LP | 9,163,157 | +2,043,150 |
| BlackRock, Inc. | 5,678,035 | +1,925,835 |
| Defilade Capital Management, L.P. | 3,670,135 | new |
| Driehaus Capital Management LLC | 3,163,423 | +229,024 |
| Vanguard Capital Management LLC | 2,974,901 | +108,552 |
| Rtw Investments, LP | 2,565,999 | +1,065,999 |
| Aqr Capital Management LLC | 2,371,414 | +1,553,897 |
| Marshall Wace, Llp | 2,012,458 | +1,078,994 |
| DAFNA Capital Management LLC | 2,008,164 | -21,000 |
| Goldman Sachs Group Inc | 1,752,910 | +191,325 |
| Geode Capital Management, LLC | 1,679,003 | +570,242 |
| Qube Research & Technologies Ltd | 1,641,042 | +793,398 |
| Citadel Advisors LLC | 1,456,825 | +937,693 |
| State Street Corp | 1,411,804 | +500,478 |
| Vanguard Portfolio Management LLC | 1,403,172 | +996,614 |
| Woodline Partners LP | 1,400,850 | 0 |
| Millennium Management LLC | 1,333,037 | -2,292,241 |
| Dimensional Fund Advisors LP | 961,083 | +162,621 |
| Fmr LLC | 937,368 | +873,798 |
Insiders
9 insiders reported holding 7,716,727 shares in total, about $19.5M at the last price.
| Holder | Shares |
|---|---|
| Flynn James EDirector, 10% owner | 6,207,9826,207,982 held indirectly |
| Hamilton Thomas EdwardDirector | 714,798 |
| Ben-Maimon CarolePresident and CEO, Director | 368,276 |
| Celano MichaelChief Financial Officer | 215,785 |
| Shankar GopiChief Development Officer | 76,443 |
| Clayton RussellChief Medical Officer | 71,443 |
| Harlow John B. Jr.President and COO | 50,000 |
| Thomas Frank EDirector | 7,000 |
| Sherman Jeffrey WDirector | 5,000 |
Questions about LRMR
What does Larimar Therapeutics, Inc. do?
Larimar Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as LRMR. Its shares trade on NASDAQ under the ticker LRMR.
What is Larimar Therapeutics, Inc.'s net worth?
Larimar Therapeutics, Inc. has a market value (market cap) of $262.8M at the latest share price, and shareholders' equity of $127.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Larimar Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $172.6M.
When did Larimar Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the quarterly results from November 9, 2026.
When is Larimar Therapeutics, Inc.'s next earnings report?
Larimar Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare LRMR with
Follow LRMR
Get an email when Larimar Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Larimar Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.